Cost Effectiveness of Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for the First-Line Treatment of Mantle Cell Lymphoma not Eligible for Stem Cell Transplantation: a Scottish Perspective
Van Keep, MM, Gairy, K, Seshagiri, D, Thilakarathne, P, Lee, DVolume:
18
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2015.09.1147
Date:
November, 2015
File:
PDF, 52 KB
english, 2015